Modality
Multispecific
MOA
GLP-1ag
Target
AuroraA
Pathway
Neuroinflam
LN
Development Pipeline
Preclinical
~Jun 2014
→ ~Sep 2015
Phase 1
~Dec 2015
→ ~Mar 2017
Phase 2
~Jun 2017
→ ~Sep 2018
Phase 3
~Dec 2018
→ ~Mar 2020
NDA/BLA
Jun 2020
→ Sep 2028
NDA/BLACurrent
NCT07406879
818 pts·LN
2020-06→2028-09·Terminated
818 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-09-132.5y awayPh3 Readout· LN
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2028-09-13 · 2.5y away
LN
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07406879 | NDA/BLA | LN | Terminated | 818 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR |